AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 18408580
Drug: Neoral C2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoral C2 monitoring with high range (1600-1800 ng/mL)
Trial: 18408580
Drug: Neoral C2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoral C2 monitoring with intermediate range (1400-1600 ng/mL)
Trial: 18408580
Drug: Neoral C2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoral C2 monitoring with low range (1200-1400 ng/mL)
Trial: 15816467
Drug: Cimetidine (CIM)
RxNorm normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cimetidine (CIM) administered perioperatively, initiated 7 days before operation and continued until 10 days after surgery.
Trial: 14695785
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no cimetidine treatment).
Trial: 14695785
Drug: Cimetidine (CIM)
RxNorm normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cimetidine (CIM) treatment.
Trial: 12459936
Drug: Clodronate 400-800
RxNorm normalized name: clodronic acid 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clodronate 400-800 mg
Trial: 10379611
Drug: Dorzolamide eye
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dorzolamide eye drops applied three times daily for 3 days
Trial: 10379611
Drug: Placebo preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo preparation applied according to the same protocol
Trial: 8540451
Drug: Beta-blocker group
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-blocker group (n = 58)
Trial: 1907662
Drug: Epidural morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural morphine (76 patients)
Trial: 6138120
Drug: Trimeprazine (sedative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimeprazine (sedative H1 antihistamine)
Trial: 6138120
Drug: Nitrazepam (sedative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrazepam (sedative benzodiazepine)
Trial: 6138120
Drug: Astemizole (non-sedative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Astemizole (non-sedative H1 antihistamine)
Trial: 6138120
Drug: Terfenadine (non-sedative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terfenadine (non-sedative H1 antihistamine)
Trial: 25637614
Drug: Directed Osteopathic
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Directed Osteopathic Manipulative Treatment (D-OMT)
Trial: 25637614
Drug: Nondirected Osteopathic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nondirected Osteopathic Manipulative Treatment (ND-OMT)
Trial: 15849222
Drug: Standard chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard chemotherapy (with or without trastuzumab)
Trial: 12040975
Drug: Oral testosterone
RxNorm normalized name: testosterone Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral testosterone undecanoate for 2 months
Trial: 3080622
Drug: Unbalanced amino
RxNorm normalized name: silk amino acids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unbalanced amino acid solutions (essential amino acids, branched‐chain amino acids)
Trial: 3080622
Drug: Balanced and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balanced and complete amino acid solution
Trial: 22048172
Drug: HPV-6/11/16/18 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPV-6/11/16/18 vaccine
Trial: 28987287
Drug: Potentially effective
RxNorm normalized name: Potentilla discolor whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potentially effective low-risk treatments for weight-loss devices
Trial: 28987287
Drug: Potentially less
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potentially less effective and riskier treatments for weight-loss devices
Trial: 26781700
Drug: Ready-to-eat food
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ready-to-eat food product (Vita-Weat biscuit) as part of a diet prescription for weight loss
Trial: 24552306
Drug: Antituberculosis therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antituberculosis therapy
Trial: 9855212
Drug: Distension combined
RxNorm normalized name: Disperse Blue 106
DrugBank: Disperse Blue 106 (DB14203)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Distension combined with steroid
Trial: 9855212
Drug: Steroid alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid alone
Trial: 2651106
Drug: Sodium acetate
RxNorm normalized name: Sodium Acetate
DrugBank: Sodium nitrate (DB15952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium acetate infusion at 2.5 mmoles/min for 60 min
Trial: 29090685
Drug: Tocilizumab (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tocilizumab (8 mg/kg, 3 monthly infusions)
Trial: 28463714
Drug: Antipsychotic medication-alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antipsychotic medication-alone
Trial: 26323969
Drug: Gamma Delta
RxNorm normalized name: Allogeneic enriched variable delta 1 gamma delta T-cells
DrugBank: GDX012 (DB18448)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gamma Delta Tocotrienol (GDT) - 2 capsules of 300 mg (450 mg γ‐T3 and 150 mg δ‐T3)
Trial: 26323969
Drug: Tocotrienol-Rich Fraction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tocotrienol-Rich Fraction (TRF) - 4 capsules of 200 mg (451.2 mg γ‐T3 & 102.72 mg δ‐T3)
Trial: 24548399
Drug: recombinant tissue
RxNorm normalized name: Tissue plasminogen activator, recombinant
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: recombinant tissue plasminogen activator (rt‐PA) and parental anticoagulant
Trial: 18303156
Drug: Intravitreal bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravitreal bevacizumab (1 mg, 0.04 ml)
Trial: 18303156
Drug: Photodynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photodynamic therapy (PDT) plus intravitreal triamcinolone (4 mg)
Trial: 10352330
Drug: Control (historical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (historical controls without G‐CSF)
Trial: 28969711
Drug: n‐3 LCPUFA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n‐3 LCPUFA supplements
Trial: 24519631
Drug: 0.1% bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% bupivacaine with 15 μg·mL(‐1) hydromorphone (LA group)
Trial: 15284305
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no digoxin therapy)
Trial: 8427134
Drug: Sequential pulse
RxNorm normalized name: dulse extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential pulse shocks
Trial: 3676051
Drug: Conventional inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional inhalation induction technique with isoflurane in nitrous oxide and oxygen
Trial: 28669167
Drug: Leukocytosis (WBC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leukocytosis (WBC > 9 x 10^9/L)
Trial: 28669167
Drug: Normal WBC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal WBC (WBC ≤ 9 x 10^9/L)
Trial: 28669167
Drug: Anemia (Hgb
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anemia (Hgb < 110 g/L)
Trial: 28669167
Drug: Normal Hgb
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal Hgb (Hgb ≥ 110 g/L)
Trial: 28669167
Drug: Thrombocytosis (Plt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombocytosis (Plt > 350 x 10^9/L)
Trial: 20169458
Drug: Experimental solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental solution (SnCl(2) with 1,900 ppm Sn(2+) and 1,000 ppm F(-), pH 4.5)
Trial: 19930833
Drug: Embolization of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Embolization of the draining veins with absolute ethanol followed by bleomycin A5 hydrochloride intra-tumoural injection
Trial: 19930833
Drug: Intra-tumoural injection
RxNorm normalized name: TUMOUR DETECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-tumoural injection only
Trial: 16767966
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg dexamethasone intravenously before induction of anesthesia
Trial: 16767966
Drug: Placebo (0.9%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0.9% normal saline 2 ml)
Trial: 9052476
Drug: Immediate treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate treatment (orchidectomy or luteinizing hormone-releasing hormone analogue)
Trial: 8336880
Drug: Extra-amniotic saline
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extra-amniotic saline infusion plus intracervical Foley catheter balloon
Trial: 8336880
Drug: Prostaglandin E2
RxNorm normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Prostaglandin E2 vaginal gel (2.85 mg)
Trial: 3096164
Drug: Alfentanil bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfentanil bolus injection (n = 15) over 3 s
Trial: 3096164
Drug: Alfentanil slow
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfentanil slow injection (n = 15) over 30 s
Trial: 3096164
Drug: Succinylcholine (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Succinylcholine (25 mg i.v.)
Trial: 31276809
Drug: High-dose Fentanyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose Fentanyl Sublingual Spray (FSS) (35%-45% of total daily opioid dose)
Trial: 31276809
Drug: Low-dose Fentanyl
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose Fentanyl Sublingual Spray (FSS) (15%-25% of total daily opioid dose)
Trial: 31276809
Drug: High-dose Fentanyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose Fentanyl Sublingual Spray (FSS)
Trial: 21813882
Drug: Autologous fat
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous fat transplantation (Group A; 12-165 mL per session)
Trial: 21813882
Drug: Adipose-derived stem
RxNorm normalized name: human adipose preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adipose-derived stem cell-enriched lipografts (Group B; 8-155 mL per session)
Trial: 16735482
Drug: Whey protein
RxNorm normalized name: Whey protein
DrugBank: Whey (DB18685)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whey protein preload (50 g, 1.1 MJ, 450 ml)
Trial: 16735482
Drug: Soy protein
RxNorm normalized name: Soy Protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy protein preload (50 g, 1.1 MJ, 450 ml)
Trial: 16735482
Drug: Gluten protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gluten protein preload (50 g, 1.1 MJ, 450 ml)
Trial: 16735482
Drug: Glucose treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose treatment
Trial: 15331551
Drug: Intravenous exenatide
RxNorm normalized name: Exenatide
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous exenatide (0.066 pmol.kg(‐1).min(‐1))
Trial: 9156366
Drug: NG‐monomethyl‐L‐arginine (L‐NMMA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NG‐monomethyl‐L‐arginine (L‐NMMA) at 200 mumol
Trial: 9156366
Drug: Intraarterial L‐NMMA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraarterial L‐NMMA (8 mumol/min for 5 min)
Trial: 8333471
Drug: Leuprolide acetate
RxNorm normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leuprolide acetate depot (3.75 mg injected monthly)
Trial: 8333471
Drug: Danazol (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Danazol (800 mg administered orally daily)
Trial: 29965967
Drug: MJ8VAX (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MJ8VAX (50 μg of peptide conjugate J8-DT)
Trial: 19160429
Drug: Tamoxifen 20
RxNorm normalized name: tamoxifen 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen 20 mg/d for 6 months
Trial: 12105320
Drug: Donepezil (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donepezil (5 mg/d for 30 days)
Trial: 6457060
Drug: 400 mg/d
RxNorm normalized name: ribociclib succinate 400 mg/day (200 mg x 2) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg/d disodium dichloromethylene diphosphonate (Cl2MDP)
Trial: 6457060
Drug: 1,600 mg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,600 mg/d disodium dichloromethylene diphosphonate (Cl2MDP)
Trial: 31610101
Drug: BHV-0223 (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BHV-0223 (40 mg)
Trial: 31610101
Drug: BHV-0223 (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BHV-0223 (40 mg) under fed conditions
Trial: 31610101
Drug: Oral riluzole
RxNorm normalized name: Riluzole
DrugBank: Riluzole (DB00740)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral riluzole tablets (50 mg)
Trial: 24291054
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg P. emblica extract
Trial: 24291054
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg ecosprin
Trial: 24291054
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg P. emblica + 75 mg clopidogrel
Trial: 24291054
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg P. emblica + 75 mg ecosprin
Trial: 24291054
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg P. emblica extract (twice daily)
Trial: 24291054
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg clopidogrel (once daily)
Trial: 24291054
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg ecosprin (once daily)
Trial: 19755613
Drug: Tadalafil 20
RxNorm normalized name: tadalafil 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tadalafil 20 mg daily for 4 weeks
Trial: 11600564
Drug: Simvastatin treatment
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin treatment in subjects with null mutations
Trial: 11600564
Drug: Simvastatin treatment
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin treatment in subjects with defective mutations
Trial: 9637897
Drug: Amoxicillin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin (40 mg/kg/day)
Trial: 9637897
Drug: Penicillin V
RxNorm normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Penicillin V (lower dosage)
Trial: 2595326
Drug: EMLA cream
RxNorm normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EMLA cream 5%
Trial: 28492789
Drug: Long-acting lignocaine-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting lignocaine-based blood cardioplegia (single dose)
Trial: 21913385
Drug: Ultrasound cavitation
RxNorm normalized name: ULTRASOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound cavitation therapy (USC) using Sonoca‐180 unit
Trial: 18642029
Drug: Octreotide 30
RxNorm normalized name: octreotide 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide 30 mg im on day 1
Trial: 18642029
Drug: Octreotide 30
RxNorm normalized name: octreotide 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide 30 mg on day 1 plus Imatinib 400 mg po daily
Trial: 18642029
Drug: Oxaliplatin on
RxNorm normalized name: Oxaliplatin only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxaliplatin on day 1 (60 mg-90 mg/m2)
Trial: 18642029
Drug: Oxaliplatin on
RxNorm normalized name: Oxaliplatin only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxaliplatin on day 1, 8, 15 (20 mg-30 mg/m2) plus octreotide 30 mg on day 1 plus imatinib 400 mg po daily
Trial: 15633480
Drug: Sentinel lymph
RxNorm normalized name: Sentinel Spectrum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sentinel lymph node biopsy (SLNB) using subdermal or peritumoral injection of vital blue dye and/or both substances together.
Trial: 11425807
Drug: Rofecoxib (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rofecoxib (25 mg, orally, once daily for 9 consecutive days)
Trial: 8574511
Drug: midazolam 100
RxNorm normalized name: midazolam 100 MG in 100 mL Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: midazolam 100 micrograms/kg by jet‐injection (JI)
Trial: 8574511
Drug: midazolam 150
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: midazolam 150 micrograms/kg by jet‐injection (JI)
Trial: 8574511
Drug: midazolam 200
RxNorm normalized name: midazolam 200 mg/200 mL-D5% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: midazolam 200 micrograms/kg by jet‐injection (JI)
Trial: 2203257
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E (800 mg dl-alpha-tocopheryl acetate)
Trial: 393520
Drug: Sustained release
RxNorm normalized name: Sustained Release Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained release propranolol capsules 160 mg once daily
Trial: 393520
Drug: Standard propranolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard propranolol tablets 40 mg four times daily
Trial: 28500900
Drug: Autologous mesenchymal
RxNorm normalized name: AUTOLOGOUS MESENCHYMAL STROMAL CELLS SECRETING NEUROTROPHIC FACTORS
DrugBank: Debamestrocel (DB17934)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous mesenchymal stem cells (MSC) therapy with a target dose of 1×10^6 cells/kg intravenously and 0.1×10^6 cells/kg intrathecally
Trial: 28500900
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment with anti-epileptic drugs (AED)
Trial: 23562198
Drug: TAA HFA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAA HFA at 14, 110, or 440 micrograms once daily
Trial: 23562198
Drug: TAA CFC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAA CFC at 14, 110, or 440 micrograms once daily
Trial: 23562198
Drug: TAA HFA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAA HFA and TAA CFC formulations
Trial: 23562198
Drug: TAA HFA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAA HFA at 7 micrograms per nostril once daily
Trial: 17174015
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose selenium (Se+ group, 474, 316, 158 microg/day for 3 days followed by 31.6 microg/day)
Trial: 17174015
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose selenium (Se+ group)
Trial: 17174015
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (Se- group, standard dose of 31.6 microg/day)
Trial: 15143088
Drug: Dalteparin (5,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dalteparin (5,000 IU, once-daily subcutaneous injection)
Trial: 29499060
Drug: Point of
RxNorm normalized name: Precision Point of Care Test Strip
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Point of Care CD4 + Household Isoniazid Preventive Therapy (HH-IPT)
Trial: 26927166
Drug: CHO +
RxNorm normalized name: G-CSF (CHO cell derived)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHO + WP (20 g whey protein isolate)
Trial: 19903626
Drug: SockIt! Oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SockIt! Oral Pain Gel applied to dentures
Trial: 19903626
Drug: No topical
RxNorm normalized name: Altreno Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No topical treatment
Trial: 2311145
Drug: Epidural epinephrine
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epidural epinephrine (5 micrograms.ml‐1) added to bupivacaine (0.75 per cent)
Trial: 6770801
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg of sustained-release capsules once a day
Trial: 6770801
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg of capsules twice a day
Trial: 6770801
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg of tablets four times a day
Trial: 28816142
Drug: Vorinostat 400
RxNorm normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vorinostat 400 mg orally once daily for 14 days with concurrent stereotactic radiosurgery (SRS)
Trial: 28816142
Drug: Vorinostat 200
RxNorm normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vorinostat 200 mg and 300 mg doses
Trial: 15028938
Drug: 5 mL
RxNorm normalized name: WATER,INHL 5 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mL acetic acid gel, intravaginally twice daily for 7 days
Trial: 15028938
Drug: Placebo gel,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo gel, intravaginally twice daily for 7 days
Trial: 11573636
Drug: Tramadol 2
RxNorm normalized name: traMADol 25 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol 2 mg kg(-1) i.v.
Trial: 11573636
Drug: Tramadol 2
RxNorm normalized name: traMADol 25 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol 2 mg kg(-1) i.v. and Placebo
Trial: 7887134
Drug: NADH, 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NADH, 25 mg, given intravenously once a day for four days, followed by 25 mg NADH intramuscularly after 2 and 4 weeks